Q-omics provides the consensus-scored CDC25B profile across patient tissues and cancer cell-line models. CDC25B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CDC25B is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, CDC25B RNA expression shows 18,916 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where CDC25B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC25B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC25B survival associations across molecular data types. CDC25B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC25B RNA expression–survival associations across cancer types. High CDC25B expression shows unfavorable associations in UVM, ACC, KIRC, LIHC and LGG, but favorable associations in UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CDC25B RNA expression.
This table summarizes CDC25B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CDC25B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC25B shows higher tumor expression in COAD, HNSC, STAD, LIHC, KIRC and THCA. The COAD box plot shows higher CDC25B RNA expression in tumor versus normal tissue (log2 FC = +2.676, t-test p < 0.001).
This table shows molecular features associated with CDC25B in patient tissues and cancer cell lines. In patient samples, CDC25B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC25B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
